Alisertib and hormone therapy for advanced breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new drug, alisertib, combined with hormone therapy for people with HR-positive, HER2-negative breast cancer that has spread or come back and is no longer curable. It may be an option if you've already tried at least two hormone therapies and a CDK4/6 inhibitor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your breast cancer must be HR-positive and HER2-negative.
- Your cancer must have spread or come back and cannot be cured with standard treatments.
- You must have tried at least two different hormone therapies for advanced or metastatic disease.
- You must have taken a CDK4/6 inhibitor together with hormone therapy.
- You cannot have had chemotherapy for advanced or metastatic breast cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug (an Aurora A kinase inhibitor) combined with hormone therapy and HER2-targeted therapy for people with advanced HR+/HER2+ breast cancer whose disease has not gotten worse after initial treatment. The goal is to see if this combination can help prevent the cancer from becoming resistant to treatment.
This trial tests a new drug called alisertib for people with small cell lung cancer that has spread. It is for those who have already tried standard treatments (chemotherapy and immunotherapy) and need another option.
This trial tests a combination of a new immunotherapy drug (adebrelimab) with a targeted pill (dalpiciclib) and standard hormone therapy for women with advanced hormone receptor positive, HER2 negative breast cancer. It may help patients who have not yet had certain prior treatments, aiming to slow the cancer's growth.
This trial tests two new drugs (sapanisertib and serabelisib) alone or together to treat advanced breast cancer that is hormone-receptor positive. These drugs target specific pathways that help cancer grow, and the trial will see if they work better than standard treatments.
This trial tests a combination treatment including anlotinib for women with hormone receptor-positive breast cancer that has spread to other parts of the body and has stopped responding to standard therapies. It is for those who have already tried a CDK4/6 inhibitor and endocrine therapy.
This trial is testing a new medicine as the first treatment for HER2-positive breast cancer that has spread or cannot be removed. It's for women who have not had chemotherapy for advanced disease.
Hear when a new Hormone Receptor Positive HER-2 Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.